04:06 PM EDT, 03/22/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares closed up 8.5% in Friday trading after the company said the US Food and Drug Administration approved Nexletol and Nexlizet for expanded use in cardiovascular risk reduction and lowering low-density lipoprotein cholesterol for both primary and secondary prevention patients.

The label expansion covers the use of drugs alone or in combination with statins and approves Nexletol and Nexlizet for treatment of primary hyperlipidemia, a genetic disorder characterized by abnormally high blood lipids, the company said.

The approvals are based on results from Clear Outcomes trial that bempedoic acid, a component of both drugs, was more

effective in reducing LDL-C and high-sensitivity C-reactive protein compared with placebo, according to the company.

Price: 2.29, Change: +0.18, Percent Change: +8.53